Increasing evidence has shown that cardiomyocyte hypertrophy and myocardial fibrosis are improved after the application of SGLT2 inhibitors, whether accompanied by diabetes or not (Table 1). This evidence concerns the gene SLC5A2 and Myocardial fibrosis.